246 related articles for article (PubMed ID: 22537796)
1. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
5. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
6. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
7. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Griebling TL
J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
[No Abstract] [Full Text] [Related]
8. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.
Parekh A; Chen MH; D'Amico AV; Dosoretz DE; Ross R; Salenius S; Graham PL; Beckman JA; Beard CJ; Choueiri TK; Ennis RD; Hoffman KE; Hu JC; Ma J; Martin NE; Nguyen PL
Brachytherapy; 2013; 12(5):415-21. PubMed ID: 23651926
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
11. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
12. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
Nguyen PL; Chen MH; Beckman JA; Beard CJ; Martin NE; Choueiri TK; Hu JC; Hoffman KE; Dosoretz DE; Moran BJ; Salenius SA; Braccioforte MH; Kantoff PW; D'Amico AV; Ennis RD
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1411-6. PubMed ID: 21708431
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
[TBL] [Abstract][Full Text] [Related]
16. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
17. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
19. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
20. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]